Evaluation of microRNA Gene Polymorphisms in Liver Transplant Patients with Hepatocellular Carcinoma

Sahar Dehbidi 1, Zhaleh Farokhzadeh 1, Mohammad Hossein Karimi 2, Afsoon Afsahi 2, Mehrdad Behmanesh 3, Mohammad Hossein Sanati 4, Bita Geramizadeh 2 and Ramin Yaghobi 2, *

1 Department of Biology, Faculty of Biological Science, Nour Danesh Institute of Higher Education, Meymeh, Isfahan, Iran
2 Shiraz Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
3 Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran
4 Department of Medical Genetics, National Institute for Genetic Engineering and Biotechnology, Tehran, Iran

* Corresponding author: Shiraz Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Tel/Fax: +98-7136281529, Email: rayaviro@yahoo.com

Received 2020 March 15; Revised 2020 July 15; Accepted 2020 July 19.

Abstract

**Background:** Genetic polymorphism in the miRNA sequence might alter miRNA expression and/or maturation, which is associated with the development and progression of hepatocellular carcinoma (HCC) in liver transplant patients.

**Objectives:** Therefore, the prevalence of miRNA-146a G > C (rs2910164), miRNA-499A > G (rs3746444), miRNA-149C > T (rs2292832), and miRNA-196a-2 C > T (rs11614913) gene polymorphisms was evaluated in liver recipients with HCC with or without experiencing graft rejection.

**Methods:** In a cross-sectional study, tissue samples were collected from 60 HCC patients who underwent liver transplant surgery at Namazi Hospital, Shiraz, Iran, in 2013–2015. A control group consisting of 120 individuals was randomly selected, as well. The genomic DNA was extracted from collected tissues and blood samples. The miRNA-146a (rs2910164), miRNA-499 (rs3746444), miRNA-149 (rs2292832), and miRNA-196a-2 (rs11614913) gene polymorphisms were evaluated in patients with HCC using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method.

**Results:** The CC genotype and C allele of the miRNA-146a (rs2910164) polymorphism were significantly associated with the increased risk of transplant rejection in patients with HCC (P = 0.05 and P = 0.05, respectively). The CC genotype and C allele of the miRNA-146a (rs2910164) were also significantly more frequent in male liver transplant patients who experienced acute rejection than in non-rejected ones (P = 0.05 and P = 0.03, respectively). However, no significant association was found between the genotypes and alleles of miRNA-499 (rs3746444), miRNA-149 (rs2292832), and miRNA-196a-2 (rs11614913) polymorphisms and HCC outcomes in liver transplant recipients.

**Conclusions:** The importance of the CC genotype and C allele of the miRNA-146a (rs2910164) polymorphism in increasing the risk of transplant rejection was confirmed, but it needs further studies in larger populations.

**Keywords:** Hepatocellular Carcinoma, MicroRNA, Liver Transplantation, Rejection, Polymorphism

1. **Background**

Hepatocellular carcinoma (HCC) is the fifth most common cancer. Hepatocarcinogenesis is a process that involves many genes (1). It is believed that the most altering events in the growth of the disease are caused by tumor suppressor genes, oncogenes, and reactivation of developmental pathways and their related receptors. Data show that the development and progression of HCC is a multi-stage process (2). Most of the time, an underlying disease leads to HCC, which can be cirrhosis, chronic hepatitis B virus (HBV), or hepatitis C virus (HCV) infections. Viral hepatitis infections play an important role in end-stage liver disease, and the need for transplantation increases the risk of HCC, especially after chronic HBV and HCV pathogenesis (3, 4). Hepatocellular carcinoma can cause hepatocyte turnover, inflammation, and oxidative DNA damage (5). Although novel therapeutic strategies have been developed, the treatment of advanced HCC has a poor prognosis (6).

MicroRNAs (miRNAs) are short and non-coding RNAs that have 20 - 24 nucleotides and play an important role in biological processes through the post-transcriptional regulation of protein-coding genes (7, 8). Discovering miRNAs that have roles in hepatocarcinogenesis represents an important area of investigation (9, 10). Single nucleotide polymorphisms (SNPs) are one of the most common types of genetic variations in the human
Evidence suggests that miRNAs are frequently deregulated in HCC, and some of them are related to clinicopathological aspects of HCC and post-liver transplant outcomes. Hepatocellular carcinoma was introduced as the deregulator of many critical genes’ expression in important cellular processes, such as cell cycle control, growth, migration, and apoptosis. On the other hand, miRNAs also interfere with many physiologic and pathologic processes. Besides, miRNA dysfunction is common in human disorders, including cancers. In cancers, miRNAs have different roles as tumor suppressors or oncogenes during their development (13). Identifying these genetic biomarkers can be helpful in the reduction of HCC liver transplant rejection through early diagnosis (14-16). It is worth noting that the role of the miRNA-146a polymorphism has been detected in the increased susceptibility to HCC (5, 17). Also, it is documented that the miRNA-196a-2 polymorphism is associated with HCC risk and it is higher in HBV-positive HCC patients (18-22). The genetic polymorphism of miRNA-149 is also associated with HBV-related HCC patients (18, 23), and the miRNA-499 polymorphism is important in patients with HCC (21, 24).

An SNP in the miRNA sequence might be a reason for alterations in miRNA expression and/or maturation, which is associated with cancer development and progression. MiRNA-196a-2 was mapped on chromosome 12q13.3, and an SNP was identified in its sequence (C > T; rs11614913). Several reports have identified miRNA-196a-2 (rs11614913) as a possible biomarker associated with multiple malignant tumors. Molecular epidemiologic studies have suggested that the polymorphism in miRNA-196a-2 (rs11614913) is associated with the increased risk of non-small cell lung cancer (NSCLC), breast cancer, HCC, gastric cancer, and head and neck cancer (25-27). The miRNA-146a was classified as miRNA-146a and miRNA-146b that overexpressed in HCC (26). A SNP called miRNA-146a (G > C, ch5q33; rs2910164) was found in miRNA-146a. The miRNA-146a (rs2910164) polymorphism is located in the stem region opposite to the mature miRNA-146a sequence. The optimal free energy was lower for the C allele than for the G allele, suggesting a less stable secondary structure for the C allele. The mature miRNA-146a sequence and alters the expression of mature miRNAs (28).

MiRNA-499 (A > G, ch20q11.2; rs3746444) is another polymorphism, which is located within the 20th intron of the beta-myosin heavy chain gene with an essential role in the progression of cell proliferation (24). The miRNA-149 (C > T, ch2q37.3; rs2292832) was reported to be associated with a variety of malignancies, particularly digestive and prostatic cancers (18, 28, 29).

2. Objectives

Therefore, in continuation of our earlier report (30), in this study, the prevalence of miRNA-146a (rs2910164), miRNA-499 (rs3746444), miRNA-149 (rs2292832), and miRNA-196a-2 (rs11614913) gene polymorphisms were evaluated in liver recipients with HCC with or without experiencing graft rejection.

3. Methods

3.1. Study Population

A total of 60 tissue samples were selected from the sample bank of the pathobiology lab, collected from HCC patients who underwent liver transplant surgery at the Transplant Unit, Namazi Hospital, Shiraz, Iran, in 2013 - 2015. The control group consisted of 120 individuals randomly selected from the blood transfusion organization center, but those with a history of cancer or other diseases were excluded. Based on underlying diseases leading to HCC, the patients were subdivided into viral (HBV or HCV-related), and non-viral HCC. The underlying disease in most of the patients with non-viral HCC was cryptogenic cirrhosis (Table 1). The Local Ethics Committee of Shiraz University of Medical Sciences approved this study. Written informed consent was obtained from participants or their parents/guardians (for patients below 16-years-old). All patients and controls had Iranian nationality.

3.2. DNA Extraction

The DNA was extracted from tissue samples using a DNA extraction kit or DNPTM kit (Cinna Gen, Iran) according to the manufacturer’s instruction. The DNA of control samples was extracted using the phenol-chloroform method (31). The DNA was stored at -20°C until analysis.

3.3. Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) Method

SNPs of the studied genes: miRNA-146a (rs2910164), miRNA-499 (rs3746444), miRNA-149 (rs2292832), and miRNA-196a-2 (rs11614913) were analyzed by the PCR-RFLP method.
### Table 1. Demographic Characteristics of HCC and Liver Rejected and Non-Rejected Transplant Patients

| Characteristics | HCC Patients | Rejected Group | Non-Rejected Group |
|-----------------|--------------|----------------|--------------------|
| Mean age        | 45.23 ± 16.31| 45.29 ± 16.73  | 45.22 ± 16.37      |
| Male            | 47 (78.3)    | 12             | 35                 |
| Female          | 23 (21.7)    | 2              | 11                 |
| Underlying disease, % |               |                |                    |
| HBV-related HCC | 16 (26.7)    | 4 (6.7)        | 12 (20)            |
| HCV-related HCC | 3 (5)        | -              | 3 (5)              |
| Non-viral HCC   | 41 (68.3)    | 10 (16.7)      | 31 (51.6)          |
| Total           | 60 (100)     | 14 (23.4)      | 46 (76.6)          |

Abbreviations: HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus.

Values are expressed as No. (%) or mean ± SD.

The PCR conditions for miRNA-146a (rs2910164) and miRNA-499 (rs3746444), miRNA-149 (rs2292832), and miRNA-196a-2 (rs11614913) were determined in the rejected and non-rejected groups of liver transplant recipients. Except for the miRNA-196a-2C > T genotype, all other studied miRNA genotypes in both groups of patients agreed with the Hardy-Weinberg equilibrium. The most frequent age range of patients was 50 - 65 years.

### 4. Results

#### 4.1. Patient Profiles

Among 60 recipients, the male to female ratio was 12/2 (6) in the rejected group and 35/11 (3.18) in the non-rejected group. The age range of the patients was 10 - 73 years, with a mean of 45.23 ± 16.31 years. The demographic data of the studied patients are shown in Table 1. In the present study, 8% of the recipients received grafts from living donors while the remaining 92% received them from cadavers. The control group consisted of 120 individuals (58.3% males). The average age was 30 - 60 years, with a mean of 45.09 ± 9.03 years.

The allele and genotype frequencies of miRNA-146a (rs2910164), miRNA-499 (rs3746444), miRNA-149 (rs2292832), and miRNA-196a-2 (rs11614913) were determined in the rejected and non-rejected groups of liver transplant recipients. Except for the miRNA-196a-2C > T genotype, all other studied miRNA genotypes in both groups of patients agreed with the Hardy-Weinberg equilibrium. The most frequent age range of patients was 50 - 65 years.

#### 4.2. Comparing miRNA-146a (rs2910164), miRNA-499 (rs3746444), miRNA-149 (rs2292832), and miRNA-196a-2 (rs11614913) Polymorphisms in Patients and Controls

The AG genotype of the miRNA-499 (rs3746444) polymorphism was significantly lower in liver transplant patients than in controls (OR = 2.66, 95% CI: 1.10 - 6.41, P = 0.03). However, the genotypes and alleles of the other studied miRNA polymorphisms had no significant effect on the HCC outcomes of liver transplant recipients (Table 3).

#### 4.3. Inheritance of miRNA-146a (rs2910164), miRNA-499 (rs3746444), miRNA-149 (rs2292832), and miRNA-196a-2 (rs11614913) Genes in Transplant Recipients

The CC genotype and C allele of the miRNA-146a (rs2910164) polymorphism were associated with the increased risk of transplant rejection in HCC-disordered liver transplant patients (OR = 5.33, 95% CI: 0.98 - 28.77, P = 0.05; OR = 2.86, 95% CI: 0.94 - 8.74, P = 0.03, respectively). Furthermore, the C allele and CC genotype of miRNA-146a (rs2910164) were significantly more frequent in male patients who experienced acute rejection than in non-rejected patients (OR= 5.33, 95% CI: 0.98 - 28.77, P = 0.05; OR = 2.86, 95% CI: 0.94 - 8.74, P = 0.03, respectively). However, the alleles and genotypes of all studied miRNA polymorphisms had no significant effect on the HCC outcomes of liver transplant recipients (Table 4).
Table 2. The Primers, Fragment Sizes, and Restriction Enzymes of miRNA Genetic Polymorphisms

| Genes (variants) | Primer Sequence (5' → 3') | Digestion Pattern/Fragment Sizes, bp | Restriction Enzymes |
|------------------|---------------------------|-------------------------------------|---------------------|
| MIRNA-146a G/C   | F: 5'-CATGGGTTGTGTCAGTGTCAGAGCT-3' | GG = 147; CG = 147,122,25; CC = 122,25 | SacI (5'-G A G C T↓C-3') |
|                  | R: 5'-TGCCTTCTGTCAGCTCCTCCCAA3' |                                 |                     |
| MIRNA-149 C/T    | F: 5'-CTGGCTCCGTGTCTTCACTC-3' | TT = 224,66; CT = 224,153,71,66; CC = 153,71 | AluI (5'-A G C T↓C-3') |
|                  | R: 5'-TGAGGCCCGAAACACCCGTA-3' |                                 |                     |
| MIRNA-499 A/G    | F: 5'-CAAAGTCTTCACTTCCCTGCCA-3' | GG = 146; AG = 146,120,26; AA = 120,26 | BclI (5'-T↓G A T C A-3') |
|                  | R: 5'-GATGTTTAACTCCTCTCCACGTGATC-3' |                                 |                     |
| MIRNA-196a2 C/T  | F: 5'-CCCTCCTCCCTCCCTCAAGATAC-3' | TT = 149; CT = 149,125,24; CC = 125,24 | MspI (5'-C↓C G G-3') |
|                  | R: 5'-CGAAACCGACATCTAATCCG |                                 |                     |

Table 3. Comparison of Frequency Distribution of Alleles and Genotypes of miRNA-146a (rs2910164), miRNA-499 (rs3746444), miRNA-149 (rs2292832), and miRNA-196a-2 (rs11614913) Polymorphisms in Transplant Patients and Controls

| SNPs       | Genotypes | Controls (N = 120) | Transplant Patients (N = 60) | P Value | OR   | 95% CI       |
|------------|-----------|-------------------|-------------------------------|---------|------|--------------|
| MIRNA-146a G > C | GG       | 74 (61.70)        | 40 (66.70)                    | 1       | Reference |
|            | CG       | 33 (27.50)        | 11 (18.30)                   | 0.40    | 0.73  | (0.34 - 1.54) |
|            | CC       | 13 (10.80)        | 7 (11.70)                    | 0.99    | 0.99  | (0.36 - 2.69) |
|            | G Allele | 181 (75.40)       | 93 (77.50)                   |         |       |              |
|            | C Allele | 59 (24.60)        | 27 (22.50)                   | 0.66    | 0.89  | (0.50 - 1.53) |
| MIRNA-196a2 C > T | CC       | 41 (34.20)        | 18 (30.00)                   | 1       | Reference |
|            | TT       | 20 (16.70)        | 8 (13.30)                    | 0.85    | 0.91  | (0.50 - 1.64) |
|            | CT       | 59 (49.20)        | 34 (56.70)                   | 0.44    | 1.13  | (0.69 - 2.60) |
|            | C Allele | 141 (58.75)       | 70 (58.30)                   |         |       |              |
|            | T Allele | 99 (41.25)        | 50 (41.60)                   | 0.93    | 0.98  | (0.61 - 1.57) |
| MIRNA-499 A > G | AA       | 37 (30.80)        | 10 (16.70)                   | 1       | Reference |
|            | GG       | 51 (42.50)        | 27 (45.00)                   | 0.21    | 1.96  | (0.84 - 4.53) |
|            | AG       | 32 (26.70)        | 23 (38.30)                   | 0.03    | 2.66  | (1.10 - 6.42) |
|            | A Allele | 106 (44.20)       | 41 (35.80)                   |         |       | Reference |
|            | G Allele | 134 (55.80)       | 77 (64.20)                   | 0.13    | 0.70  | (0.43 - 1.13) |
| MIRNA-149 C > T | CC       | 20 (16.70)        | 11 (18.30)                   | 1       | Reference |
|            | TT       | 42 (35.00)        | 24 (40.00)                   | 0.50    | 0.88  | (0.37 - 2.07) |
|            | CT       | 58 (48.30)        | 21 (33.30)                   | 0.20    | 0.61  | (0.26 - 1.42) |
|            | C Allele | 98 (40.80)        | 49 (40.80)                   |         |       | Reference |
|            | T Allele | 142 (59.20)       | 71 (59.20)                   | 1.00    | 1.00  | (0.62 - 1.59) |

aValues are expressed as No. (%).

4.4. Comparing miRNA-146a (rs2910164), miRNA-499 (rs3746444), miRNA-149 (rs2292832), and miRNA-196a-2 (rs11614913) Polymorphisms in Viral Infected and Non-Viral Liver Transplant Patients

The C allele and CC genotype of the miRNA-146a (rs2910164) polymorphism were associated with the increased risk of transplant rejection in non-viral HCC liver transplant patients compared to non-rejected ones (OR = 6.21, 95% CI: 0.65 - 69.1, P = 0.04; OR = 3.71, 95% CI: 0.86 - 11.76, P = 0.04, respectively). However, the genotypes and alleles of the miRNA-499 (rs3746444), miRNA-149 (rs2292832), and miRNA-196a-2 (rs11614913) polymorphisms had no significant differences between non-viral-infected liver transplant recipients experiencing rejection.
Table 4. Comparison of Frequency Distribution of Alleles and Genotypes of miRNA-146a (rs2910164), miRNA-499 (rs3746444), miRNA-149 (rs2292832), and miRNA-196a-2 (rs11614913) Polymorphisms in Rejected and Non-Rejected Liver Transplant Patients

| SNPs        | Genotypes | Rejected Group (N = 14) | Non-Rejected Group (N = 46) | P Value | OR    | 95%CI        |
|-------------|-----------|-------------------------|-----------------------------|---------|-------|-------------|
| MiRNA-146G > C | GG        | 8 (57.1)                | 32 (69.6)                   | 1       | Reference |
|             | CG        | 2 (14.3)                | 11 (23.9)                   | 0.71    | 0.72  | (0.13 - 3.95) |
|             | CC        | 4 (28.6)                | 3 (6.5)                     | 0.05    | 5.33  | (0.98 - 28.77) |
|             | G Allele  | 18 (64.3)               | 75 (81.5)                   |         |       |             |
|             | C Allele  | 10 (35.7)               | 17 (18.5)                   | 0.05    | 0.41  | (0.15 - 1.15) |
| MiRNA-196a2C > T | CC       | 6 (42.9)                | 12 (26.1)                   | 1       | Reference |
|             | TT        | 1 (7.1)                 | 12 (26.1)                   | 0.28    | 0.28  | (0.02 - 2.88) |
|             | CT        | 7 (50)                  | 27 (58.7)                   | 0.31    | 0.51  | (0.14 - 1.87) |
|             | C Allele  | 19 (67.9)               | 51 (55.4)                   |         |       | Reference |
|             | T Allele  | 9 (32.1)                | 41 (44.6)                   | 0.24    | 0.59  | (0.22 - 1.56) |
| MiRNA-499A > G | AA       | 2 (14.3)                | 8 (17.4)                    | 1       | Reference |
|             | GG        | 7 (50)                  | 20 (43.5)                   | 0.71    | 1.40  | (0.23 - 8.24) |
|             | AG        | 5 (35.7)                | 18 (39.1)                   | 0.91    | 1.11  | (0.57 - 2.24) |
|             | G Allele  | 19 (67.9)               | 51 (55.4)                   |         |       | Reference |
|             | C Allele  | 11 (39.3)               | 38 (41.3)                   | 0.64    | 0.84  | (0.30 - 2.16) |
| MiRNA-149C > T | CC       | 3 (21.4)                | 54 (58.7)                   | 1       | Reference |
|             | TT        | 6 (42.9)                | 17 (37)                     | 0.69    | 0.90  | (0.23 - 5.4)  |
|             | CT        | 5 (35.7)                | 20 (43.5)                   | 0.60    | 0.93  | (0.28 - 4.70) |
|             | C Allele  | 11 (39.3)               | 38 (41.3)                   |         |       | Reference |
|             | T Allele  | 17 (60.7)               | 9 (19.5)                    | 0.84    | 1.08  | (0.42 - 2.80) |

and non-rejected ones. No statistically significant differences were found in the allele or genotype distributions of the studied miRNA polymorphisms, including miRNA-146a (rs2910164), miRNA-499 (rs3746444), miRNA-149 (rs2292832), and miRNA-196a-2 (rs11614913) between viral-infected liver transplant recipients experiencing rejection and viral infected non-rejected ones.

5. Discussion

The miRNA genes, located in cancer-associated genomic regions that might function either as tumor suppressors or oncogenes, can lead to malignant transformation (13, 17, 31). MiRNAs have roles in introducing and developing cancers and can be used to predict the prognosis or treatment response (32, 33). In HCC, an individual’s susceptibility to transplant rejection might be determined by genetic polymorphisms of the genes involved in multistage hepatocarcinogenesis, which have not a history of in earlier reports (11, 22). Investigating diverse polymorphisms of miRNAs and their target genes will be a serious step towards the clinical utilization of this new subclass of genetic variations in liver transplant recipients due to HCC in a population (34). Since the expression of miRNA molecules might be affected by gene polymorphisms, our objective was to explore the effect of miRNA gene polymorphisms on the outcome of liver transplantation.

MiRNA-146a is an important regulatory molecule. Studies have shown its critical role in many biological processes. MiRNA-146a can exert its proapoptotic role by blocking NF-κB, which renders to stop its effects on cell proliferation, angiogenesis, metastasis, and cancer cell survival (35, 36). Up and downregulation of miRNA-146a has been found during the activation of the innate immune system, inflammatory diseases, and cancers (37). It is believed that the dysfunction of miRNA-146a after genetic polymorphisms facilitates cancer cell migration (35, 36).

In the present study, despite the lower frequency of the CC genotype and C allele than that of the GG genotype and G allele, the CC genotype and C allele of miRNA-146a (rs2910164) polymorphisms were significantly related to the increased risk of liver rejection in HCC transplant patients. In addition, the CC genotype and C allele were significantly more frequent in male patients who experienced
The genetic polymorphism of miRNA-149 (rs2292832) was also evaluated in liver transplant recipients with HCC. The miRNA-149 (rs2292832) polymorphism locates in the stem-loop of mature miRNAs regions and by targeting Akt and E2F1 might inhibit proliferation and induce cell cycle arrest (48). Thus, alterations in the miRNA-149 gene might contribute to transplant rejection (49).

In the present study on an Iranian population, the data showed that the effects of genotypes and alleles of the miRNA-149 (rs2292832) polymorphism were not significant on HCC outcomes in liver transplant recipients. These findings are similar to those reported by Akkiz et al. (28) in a Turkish population, and He et al. (50) in a Chinese population. The mentioned polymorphism was not significantly different between HCC patients and controls but also was not similar to polymorphism reported by Kim et al. in a Korean population. The controversy in the genotype distribution of miRNA-196a-2 (rs11614913) and the risk of cancer might be related to ethnicity. In a meta-analysis, a significant association was found between the miRNA-196a-2 (rs11614913) TT genotype and a decreased risk of cancer in Asians compared to a Caucasian population (44).

Our results showed a relationship between the risk of HCC and polymorphisms in miRNA-196a-2, which is in agreement with other laboratory and clinical studies. As the targets of miRNA-196a-2, the HOX proteins are known for their crucial roles during embryogenesis, organogenesis, and oncogenesis (40, 45, 46). Therefore, alterations in HOX gene expression is critical in the carcinogenesis and malignant progression of HCC (47). Also, the other target of miRNA-196a-2, ANXA1, is important in transformations leading to HCC, and it is closely related to the histological grade and metastatic ability of HCC. In addition, it was shown that the up-regulation of miRNA-196a-2 could facilitate cancer cell migration and invasion (41). Changes in the expression patterns of miRNA-196a-2 can influence its targets, which might play a role in HCC susceptibility and function as an oncogenic miRNA (22). Consequently, it is sensible to propose that individuals carrying the miRNA-196a-2 (rs11614913) CC allele and CC genotype might be susceptible to HCC (41).
The miRNA-499 (rs3746444) located in 3’ mature miRNAs regions might influence both the binding of 3’ mature miRNAs to Sox6 and Rldi target genes and the cell cycle (51, 52). In the present study, the data showed that the genotypes and alleles of the miRNA-499 (rs3746444) polymorphism had no significant effect on the HCC outcomes in liver transplant recipients. The findings of our study are in line with those reported by Akkiz et al. (24) and Wang et al. (23) that found no significant association between miRNA-499 (rs3746444) and susceptibility to HCC. However, our findings are in contrast to those reported by Kim et al. (18) that found the miRNA-499 (rs3746444) AA genotype was significantly associated with the risk of HCC and Shan et al. (53) that found the miRNA-499 (rs3746444) AG genotype was significantly associated with the reduced risk of HCC. The miRNA-499 (rs3746444) G allele was observed as a risk factor for cancer in an Asian population (54). The importance of ethnicity was also reported. The results of this study re-emphasize the importance of human genetic SNPs on the initiating and complicating clinical outcomes in transplant recipients, as presented in earlier reports (55-57). However, this study suffered limitations about the size and the type of samples that should be considered in the evaluation of results. We need further completed studies to validate these findings. The study was retrospective, and explanted liver of all recipient candidates with HCC who admitted for transplant were included. The collected samples were stored in a sample bank and we had no access to blood samples of liver recipients and donors and liver tissue of donors to evaluate.

5.1. Conclusions

The results showed that the CC genotype and C allele of the miRNA146a (rs2910164) polymorphism are significantly associated with a higher risk of graft rejection in liver transplant patients with HCC. Further independent studies are required to validate these findings in a larger population and in patients with different ethnicities.

Acknowledgments

The authors wish to thank Mr. H. Argasi and M. Sayadi, for their invaluable assistance in English editing and statistical analysis of this manuscript, respectively.

Footnotes

Authors’ Contribution: Study concept and design: Sahar Dehbidi, Mohammad Hossein Karimi, Mehrdad Behmanesh, Mohammad Hossein Sanati, Bita Geramizadeh, and Ramin Yaghobi. The conduct of experiments: Sahar Dehbidi, Zhaleh Farokhizadeh, and Mehrdad Behmanesh. Drafting of the manuscript: Sahar Dehbidi, Mohammad Hossein Karimi, Asfouh Afshari, Mohammad Hossein Sanati, and Ramin Yaghobi. Critical revision of the manuscript for important intellectual content: Sahar Dehbidi, Asfouh Afshari, and Ramin Yaghobi. Statistical analysis: Sahar Dehbidi, Asfouh Afshari, and Ramin Yaghobi.

Conflict of Interests: No conflicts of interest are declared by the authors.

Ethical Approval: The study protocol was approved by the Local Ethics Committee of Shiraz University of Medical Sciences.

Funding/Support: This study was funded by the Shiraz University of Medical Sciences, Shiraz, Iran, with grant number 92-196.

Informed Consent: Informed consent was obtained from all participants for any experiments and all experiments were performed in compliance with the institutional guidelines.

References

1. Llovet JM, Fuster J, Bruix J. Barcelona-Clinic Liver Cancer Group. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004;10(2 Suppl 1):S15–20. doi: 10.1002/lt.20034. [PubMed: 14768285].
2. Huang S, He X. The role of microRNAs in liver cancer progression. Br J Cancer. 2011;104(2):235–40. doi: 10.1038/bjc.2010.401. [PubMed: 20928501]. [PubMed Central: PMC301885].
3. Behzad-Beihabani A, Mojiri A, Tabei SZ, Farhadi-Andarabi A, Pouransari R, Yaghobi R, et al. Outcome of hepatitis B and C virus infection on graft function after renal transplantation. Transplant Proc. 2005;37(7):3045–7. doi: 10.1016/j.transproceed.2005.07.039. [PubMed: 1623299].
4. Ghanbari R, Ravanshad M, Hosseini SY, Yaghobi R, Shahzamani K. Genotyping and infection rate of GBV-C among Iranian HCV-infected patients. Hepat Mon. 2010;10(2):80–7. [PubMed: 2232317]. [PubMed Central: PMC327036].
5. Dragani TA. Risk of HCC: Genetic heterogeneity and complex genetics. J Hepatol. 2010;52(2):252–7. doi: 10.1016/j.jhep.2009.11.045. [PubMed: 20022654].
6. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19(8):1893–907. doi: 10.1158/1055-9965.EPI-10-0437. [PubMed: 20647400].
7. Khare S, Zhang Q, Ibdah JA. Epigenetics of hepatocellular carcinoma: Role of microRNA. World J Gastroenterol. 2013;19(35):5439–45. doi: 10.3748/wjg.v19.i35.5439. [PubMed: 24032483]. [PubMed Central: PMC3791096].
8. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281-97. doi: 10.1016/j.cell.2004.04.004. [PubMed: 14744438].
9. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene. 2006;25(12):2537-45. doi: 10.1038/sj.onc.1209283. [PubMed: 16312524].
10. Callegari E, Elamin BK, Sabbioni S, Gramantieri L, Negrini M. Role of microRNAs in hepatocellular carcinoma: A clinical perspective. Oncotargets Ther. 2013;6:1667-78. doi: 10.2147/OTT.S36161. [PubMed: 24094947]. [PubMed Central: PMC377077].
11. Loktionov A. Common gene polymorphisms, cancer progression and prognosis. Cancer Lett. 2004;208(1-2):33-4. doi: 10.1016/j.canlet.2004.02.009. [PubMed: 15050442].
12. Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, Brackett DJ, et al. Association of microRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res. 2008;14(2):249-257. doi: 10.1158/1078-0432.CCR-07-0523. [PubMed: 18221217]. [PubMed Central: PMC2752530].
13. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259-69. doi: 10.1038/nrc1840. [PubMed: 16557279].
14. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10(10):704-14. doi: 10.1038/nrg2634. [PubMed: 19756363]. [PubMed Central: PMC467906].
15. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005;5(11):845-56. doi: 10.1038/nrc1779. [PubMed: 16239964].
16. Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med. 2009;60:657-79. doi: 10.1146/annurev.med.59.053006.104707. [PubMed: 19630570].
17. Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, de la Chapelle A. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci U S A. 2008;105(20):7269-74. doi: 10.1073/pnas.0802682105. [PubMed: 18474871]. [PubMed Central: PMC2438239].
18. Kim WH, Min KT, Jeon YJ, Kwon CI, Ko KH, Park PW, et al. Association study of microRNA polymorphisms with hepatocellular carcinoma in Korean population. Gene. 2010;454(1):92-7. doi: 10.1016/j.gene.2010.02.048. [PubMed: 20583825].
19. Li M, Li J, Ding X, He M, Cheng SY. microRNA and cancer. AAPS J. 2010;12(3):809-17. doi: 10.1208/s12248-010-9194-0. [PubMed: 20492339]. [PubMed Central: PMC2895440].
20. Qi P, Dou TH, Geng L, Zhou FG, Gu X, Wang H, et al. Association of a variant in MIR 196A2 with susceptibility to hepatocellular carcinoma in a Turkish population: a case-control study. Gene. 2010;466(1-2):104-9. doi: 10.1016/j.gene.2010.01.006. [PubMed: 21807077].
21. Xiang Y, Fan S, Cao J, Huang S, Zhang LP. Association of the microRNA-499 variants with susceptibility to hepatocellular carcinoma in a Chinese population. Mol Biol Rep. 2012;39(6):7019-23. doi: 10.1007/s11033-012-1532-0. [PubMed: 2231030].
22. Farokhzadeh Z, Dehbidi S, Geramizadeh B, Saghobi R, Malekhosseini SA, Behnamesh B, et al. Association of MicroRNA polymorphisms with hepatocellular carcinoma in an Iranian population. Ann Lab Med. 2019;39(1):58-66. doi: 10.3343/alm.2019.39.1.58. [PubMed: 3025231]. [PubMed Central: PMC641471].
23. Wu M, Olincouer N, Li Z, Zhang L, Fortin Y, L’Abbe D, et al. Genetic variations of microRNAs in human cancer and their effects on the expression of miRNAs. Carcinogenesis. 2008;29(9):1710-6. doi: 10.1093/carcin/bgn073. [PubMed: 18536149].
24. Lynham-Lennon N, Maher SG, Reynolds JV. The roles of microRNA in cancer and apoptosis. Biol Rev Camb Philos Soc. 2009;84(4):555-71. doi: 10.1017/S1464-7931(08)00061-X. [PubMed: 19046400].
25. Baranwal S, Alahari SK. miRNA control of tumor cell invasion and metastasis. Int J Cancer. 2010;126(6):1283-90. doi: 10.1002/ijc.25014. [PubMed: 1987722]. [PubMed Central: PMC295297].
26. Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: The implications for cancer research. Nat Rev Cancer. 2010;10(6):389-402. doi: 10.1038/nrc2867. [PubMed: 2049537].
27. Hurst DR, Edmonds MD, Scott GK, Benz CC, Vaidya KS, Welch DR. Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res. 2009;69(4):1279-83. doi: 10.1158/0008-5472.CAN-08-3559. [PubMed: 1989013]. [PubMed Central: PMC275422].
28. Bhuamik D, Scott GK, Schokpurn S, Patil CK, Campisi J, Benz CC. Expression of microRNA-146A suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene. 2009;28(42):5643-7. doi: 10.1038/onc.2008.271. [PubMed: 19504434]. [PubMed Central: PMC2892324].
29. Wang AX, Xu B, Tong N, Chen SQ, Yang Y, Zhang XW, et al. Meta-analysis confirms that a common C/G variant in the pre-miR-146A gene contributes to cancer susceptibility and that ethnicity, gender and smoking status are risk factors. Genet Mol Res. 2012;11(3):3051-62. doi: 10.4238/2012.August.31.2. [PubMed: 2307982].
30. Xu T, Zhu Y, Wei QY, Yuan Y, Zhu F, Ge YY, et al. A functional polymorphism in the miR-146A gene is associated with the risk for hepatocellular carcinoma. Carcinogenesis. 2008;29(10):2126-31. doi: 10.1093/carcin/bgn195. [PubMed: 1871848].
31. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A. 2006;103(3):12481-6. doi: 10.1073/pnas.0605298103. [PubMed: 16902690].
40. Luthra R, Singh RR, Luthra MG, Li YX, Hannah C, Romans AM, et al. MicroRNA-196a targets annexin A1: A microRNA-mediated mechanism of annexin A1 downregulation in cancers. Oncogene. 2008;27(52):6667-78. doi: 10.1038/onc.2008.256. [PubMed: 18863355].

41. Schimanski CC, Frerichs K, Rahman F, Berger M, Lang H, Galle PR, et al. High mir-196a levels promote the oncogenic phenotype of colorectal cancer cells. World J Gastroenterol. 2009;15(7):2089-96. doi: 10.3748/wjg.v15.i7.2089. [PubMed: 19418581]. [PubMed Central: PMC2678579].

42. Dai Z, Liu YK, Cui JF, Shen HL, Chen J, Sun RX, et al. Identification and analysis of altered alpha-fucosylated glycoproteins associated with hepatocellular carcinoma metastasis. Proteomics. 2006;6(21):5857-67. doi: 10.1002/pmc.200500707. [PubMed: 17068759].

43. Masaki T, Tokuda M, Ohnishi M, Watanabe S, Fujimura T, Miyamoto K, et al. Enhanced expression of the protein kinase substrate annexin A1 in human hepatocellular carcinoma. Hepatolology. 1996;24(1):72-81. doi: 10.1053/hepl.1996.v24.pm0008707286. [PubMed: 8707286].

44. He B, Pan Y, Cho WC, Xu Y, Gu L, Nie Z, et al. The association between four genetic variants in microRNAs (rs11614913, rs2910164, rs3746444, rs2292832) and cancer risk: evidence from published studies. PLoS One. 2012;7(11):e49032. doi: 10.1371/journal.pone.0049032. [PubMed: 2355448]. [PubMed Central: PMC3498148].

45. Yekta S, Shih JH, Bartel DP. MicroRNA-directed cleavage of HOXB8 mRNA. Science. 2004;304(5670):594-6. doi: 10.1126/science.1097434. [PubMed: 15055052].

46. Wynter CV. The dialectics of cancer: A theory of the initiation and development of cancer through errors in RNAi. Med Hypotheses. 2006;66(3):362-35. doi: 10.1016/j.mehy.2005.10.024. [PubMed: 16359827].

47. Kanai M, Harnada J, Takada M, Asano T, Murakawa K, Takahashi Y, et al. Aberrant expressions of HOX genes in colorectal and hepatocellular carcinomas. Oncol Rep. 2010;23(3):843-51. [PubMed: 20127026].

48. Carcagno AL, Marazita MC, Ogara MF, Ceruti JM, Sonzogni SV, Scassa ME, et al. E2F1-mediated upregulation of p19(aKip1) determines its periodic expression during cell cycle and regulates cellular proliferation. PLoS One. 2011;6(7). e21938. doi: 10.1371/journal.pone.0021938. [PubMed: 21765927]. [PubMed Central: PMC3135596].

49. Lin RJ, Lin YC, Yu AL. miR-149* induces apoptosis by inhibiting Akt and E2F1 in human cancer cells. Mol Carcinog. 2010;49(8):719-27. doi: 10.1002/mc.20647. [PubMed: 20626644].

50. He B, Pan Y, Zhang Y, Bao Q, Chen L, Nie Z, et al. Effects of genetic variations in the adiponectin pathway genes on the risk of colorectal cancer in the Chinese population. BMC Med Genet. 2011;12:94. doi: 10.1186/1471-2350-12-94. [PubMed: 21749709]. [PubMed Central: PMC366993].

51. Parveen F, Agrawal S. Recurrent miscarriage and microRNA among North Indian women. Reprod Sci. 2015;22(4):410-5. doi: 10.1177/193371914529376. [PubMed: 24700052]. [PubMed Central: PMC4482886].

52. Murakami A, Ishida S, Thurlow J, Revest JM, Dickson C. SOX6 binds CTP2 to repress transcription from the Fgf-3 promoter. Nucleic Acids Res. 2001;29(16):3347-55. doi: 10.1093/nar/29.16.3347. [PubMed: 11504872]. [PubMed Central: PMC55654].

53. Shan YF, Huang YH, Chen ZK, Huang KT, Zhou MT, Shi HQ, et al. miR-499A>G, rs3746444 and miR-146aG>C expression and hepatocellular carcinoma risk in the Chinese population. Genet Mol Res. 2012;11(4):5365-71. doi: 10.4238/2011.November.7.11. [PubMed: 24309098].

54. Zou HZ, Zhao YQ. Positive association between miR-499A>G and hepatocellular carcinoma risk in a Chinese population. Asian Pac J Cancer Prev. 2013;14(3):1769-72. doi: 10.7314/apjcp.2013.14.3.1769. [PubMed: 23679273].

55. Saadi MI, Yaghobi R, Karimi MH, Geramizadeh B, Ramzi M, Zakerinia M. Association of the costimulatory molecule gene polymorphisms and active cytomegalovirus infection in hematopoietic stem cell transplant patients. Mol Biol Rep. 2013;40(10):5833-42. doi: 10.1007/s11033-013-2689-x. [PubMed: 24057239].

56. Iravani-Saadi M, Karimi MH, Yaghobi R, Geramizadeh B, Ramzi M, Niknami A, et al. Polymorphism of costimulatory molecules (CTLA4, ICOS, PD1 and CD28) and allogeneic hematopoietic stem cell transplantation in Iranian patients. Immunol Inves. 2013;4(4):391-404. doi: 10.3109/08820139.2013.879594. [PubMed: 24564485].

57. Karimi MH, Motazedian M, Abedi F, Yaghobi R, Geramizadeh B, Nikeghbalian S. Association of genetic variation in co-stimulatory molecule genes with outcome of liver transplant in Iranian patients. Transplantation. 2013;95(6):652-7. doi: 10.1097/TP.0b013e3182896a25. [PubMed: 23679273].

58. Dehbidi S et al.